pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
WINREVAIR · news · pharmadog
← back to WINREVAIR
News mentioning WINREVAIR
12
stories
1d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
21d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
21d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
Oct 20, 26
Most new drugs are still too costly at launch, ICER says
biopharma dive
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 13, 26
Biotech builder Paragon imports Apogee's top brass after AbbVie buyout
fiercebiotech
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Aug 5, 26
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
Jul 28, 26
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
Jul 27, 26
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
May 19, 26
Acceleron leaders and Westlake jumpstart new IPF biotech
endpoints
Apr 30, 26
Merck still sees ‘compelling’ outlook for Terns leukemia drug
biopharma dive